NASDAQ: LIMNLiminatus Pharma Inc Stock
$2.71+0.17 (+6.69%)
Updated Nov 9, 2026
LIMN Price
$2.71
Fair Value Price
-$2.33
Market Cap
$3.64M
52 Week Low
$2.40
52 Week High
$141.50
P/E
-0.12x
P/B
12.11x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$12.52M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
10.32
Operating Cash Flow
-$4M
Beta
0.7
Next Earnings
Nov 12, 2026
Ex-Dividend
N/A
Next Dividend
N/A
LIMN Overview
Liminatus Pharma, Inc. is an immuno-oncology firm, currently in its clinical development phase, dedicated to pioneering new treatments for cancer. The company's headquarters are located in La Palma, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine LIMN's potential to beat the market
- LIMN doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
LIMN
RankedUnranked of 449
RankedUnranked of 449
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $15.86 | A | |
| $919.96 | A | |
| $8.40 | A |
Be the first to know about important LIMN news, forecast changes, insider trades & much more!
LIMN News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how LIMN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
LIMN ($2.71) is overvalued by 216.53% relative to our estimate of its Fair Value price of -$2.33 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
LIMN ($2.71) is not significantly undervalued (216.53%) relative to our estimate of its Fair Value price of -$2.33 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
LIMN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more LIMN due diligence checks available for Premium users.
Valuation
LIMN fair value
Fair Value of LIMN stock based on Discounted Cash Flow (DCF)
Price
$2.71
Fair Value
-$2.33
Undervalued by
216.53%
LIMN ($2.71) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
LIMN ($2.71) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
LIMN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
LIMN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.12x
Industry
17.69x
Market
41.55x
LIMN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
12.11x
Industry
5.33x
LIMN is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
LIMN's financial health
Profit margin
Revenue
$0.0
Net Income
-$1.4M
Profit Margin
0%
LIMN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$3.4M
Liabilities
$3.1M
Debt to equity
10.32
LIMN's short-term assets ($3.39M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
LIMN's short-term assets ($3.39M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
LIMN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$970.0k
Investing
$0.0
Financing
$2.1M
LIMN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
LIMN vs Biotech Stocks
Liminatus Pharma Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.